Early Detection, Cancer Screening & Intervention:
Early Detection, Cancer Screening & Intervention focuses on identifying cancer at its earliest stages, detecting precancerous changes, assessing individual cancer risk, and implementing timely preventive and diagnostic strategies. This session covers advances in screening technologies, molecular biomarkers, liquid biopsies, medical imaging, genetic testing, and artificial intelligence for early cancer diagnosis. It also explores population-based screening programs, personalized risk assessment, preventive oncology, and early interventions aimed at improving treatment outcomes and reducing cancer-related mortality.
Related Tags:
Early Cancer Detection | Cancer Screening | Cancer Prevention | Early Diagnosis of Cancer | Cancer Risk Assessment | Population-Based Screening | Precision Screening | Biomarker-Based Screening | Liquid Biopsy | Multi-Cancer Early Detection (MCED) | Molecular Diagnostics | Genetic Cancer Screening | Hereditary Cancer Risk | Screening Guidelines | Artificial Intelligence in Cancer Detection | Medical Imaging in Oncology | Low-Dose CT Screening | Breast Cancer Screening | Cervical Cancer Screening | Colorectal Cancer Screening | Prostate Cancer Screening | Lung Cancer Screening | HPV Testing | Mammography | Early Intervention in Cancer | Preventive Oncology | Precancerous Lesions | Cancer Risk Stratification | Personalized Screening | Screening Program Evaluation | Minimally Invasive Diagnostics | Translational Cancer Research
Related Associations/Societies:
Union for International Cancer Control (UICC) | American Society of Clinical Oncology (ASCO) | European Society for Medical Oncology (ESMO) | American Association for Cancer Research (AACR) | International Association for the Study of Lung Cancer (IASLC) | International Cancer Genome Consortium (ICGC) | International Agency for Research on Cancer (IARC) | European Organisation for Research and Treatment of Cancer (EORTC) | International Psycho-Oncology Society (IPOS) | International Society of Oncology Pharmacy Practitioners (ISOPP)
